TG Therapeutics Announces Initial Phase 1 Azer-cel Data in Progressive MS
TG Therapeutics announced initial results from a Phase 1 study of investigational azer-cel in patients with progressive multiple sclerosis. The data will be presented in a late-breaking oral presentation at MSToronto2026.
Story updates
02:55:31 PM UTC
SquawkNews
TG Therapeutics reported preliminary Phase 1 results for azer-cel, an allogeneic CD19 CAR T, in 26 progressive MS patients, showing B-cell depletion and stable or improved disability in most of 18 evaluable patients, with five showing EDSS improvements. Follow-up is short and dose escalation contin…